Using botox to treat a mohs defect repair complicated by a parotid fistula.
Hatzis
Gregory P
GP
Division of Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. gregoryhatzis@yahoo.com
Finn
Richard
R
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000601:surgery; D017577:Cutaneous Fistula / Q000188:drug therapy / Q000209:etiology*; D005153:Facial Neoplasms / Q000601:surgery; D006024:Glycopyrrolate / Q000627:therapeutic use; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology; D008297:Male; D008875:Middle Aged; D015580:Mohs Surgery / Q000009:adverse effects*; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009779:Occlusive Dressings; D016155:Oral Fistula / Q000188:drug therapy / Q000209:etiology*; D010305:Parotid Diseases / Q000188:drug therapy / Q000209:etiology*
D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; D006024:Glycopyrrolate